Purr-suing feline longevity with data-driven research

The Cat Health Company aims to develop cutting-edge therapeutics that can extend cat lifespan and healthspan.

Last week we reported that The Cat Health Company had closed its pre-seed round and is now moving towards identifying and developing new therapeutics for age-related diseases in cats. As the pet longevity field continues to gather momentum, The Cat Health Company aims to join companies like Loyal and Arterra at the forefront of this movement. Founded by Alexandru Bacita and Alexandru-Ioan Voda, DPhil , the Bucharest-based company is not only focused on improving the lifespan of our feline friends but also on enhancing their overall quality of life by targeting the underlying mechanisms of aging.

My take on this: Pet longevity is becoming a growing area of interest for both researchers and consumers; as owners increasingly seek solutions to extend the healthspan of their pets, demand for scientifically backed innovations has grown, and it is a trend that mirrors the rising popularity of similar human-focused longevity research, signaling a shift in how we approach aging across species.

We sat down with Alex Voda, cofounder of The Cat Health Company, to discuss the future of feline longevity and how TCHC plans to turn cutting-edge research into practical treatments for the cats we cherish.

The market for longevity-focused products for cats is still relatively small when compared with the human longevity market – but it is growing. And the pet drugs market is also steadily increasing; Voda explains this is why big pharma companies like Merck and Novartis have created veterinary arms in their businesses and references US pet pharma Zoetis, which has a market capitalization of $86 billion as of September 2024.

“Supplements have a rewarding but tough journey,” he explains. “You have to convince veterinarians and/or consumers that there’s some sensible data suggesting safety and efficacy for your molecules, but without having the backing of relevant institutions like the FDA or EMA.”

Voda explains that the pharma space is characterized by more testing, more trials and more data than there is for supplements.

“This is good for both regulators and consumers, and while it costs more, and can take slightly more time, it ensures that there is an expert consensus on the mechanisms, safety and usefulness of your molecules.”

As TCHC develops its therapeutics, it plans to feed into national treatment guidelines for veterinary age-related diseases, enroll more and more veterinarians in its programs and build trust with pet owners. “A pleasant set of tasks to have on your hands!” remarks Voda.

Discover what's next for The Cat Health Company, straight from Alex Voda right HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!